Keyword search (4,163 papers available)

"Leyton M" Authored Publications:

Title Authors PubMed ID
1 Decriminalization or more treatment? Comparing 2 approaches to the drug overdose crisis Caswell C; Krausz RM; Leyton M; 40541419
CSBN
2 A multimodal neuroimaging study of youth at risk for substance use disorders: Functional magnetic resonance imaging and [18F]fallypride positron emission tomography Nikolic M; Cox SML; Jaworska N; Castellanos-Ryan N; Dagher A; Vitaro F; Brendgen M; Parent S; Boivin M; Côté S; Tremblay RE; Séguin JR; Leyton M; 39725679
CSBN
3 Ending the overdose epidemic by ending the war on drug users: Can this work? Leyton M; Krausz RM; 38383036
CSBN
4 Mesocorticolimbic function in cocaine polydrug users: A multimodal study of drug cue reactivity and cognitive regulation Scala SG; Kang MS; Cox SML; Rosa-Neto P; Massarweh G; Leyton M; 38221806
CSBN
5 Learning from opioid withdrawal: Effects on striatal dopamine (Commentary on Ahn et al., 2023) Leyton M; Nikolic M; 38129315
CSBN
6 Brain PET Imaging in Small Animals: Tracer Formulation, Data Acquisition, Image Reconstruction, and Data Analysis Bdair H; Kang MS; Ottoy J; Aliaga A; Kunach P; Singleton TA; Blinder S; Soucy JP; Leyton M; Rosa-Neto P; Kostikov A; 38006502
PERFORM
7 Cocaine cue-induced mesocorticolimbic activation in cocaine users: Effects of personality traits, lifetime drug use, and acute stimulant ingestion D' Amour-Horvat V; Cox SML; Dagher A; Kolivakis T; Jaworska N; Leyton M; 34463411
CSBN
8 Why did the kitten cross the road? A meditation on positive versus negative reinforcement in addiction. Leyton M 33497168
CSBN
9 Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans. Smart K, Nagano-Saito A, Milella MS, Sakae DY, Favier M, Vigneault E, Louie L, Hamilton A, Ferguson SSG, Rosa-Neto P, Narayanan S, El Mestikawy S, Leyton M, Benkelfat C 32559027
CSBN
10 mGlu5 receptor availability in youth at risk for addictions: effects of vulnerability traits and cannabis use. Cox SML, Tippler M, Jaworska N, Smart K, Castellanos-Ryan N, Durand F, Allard D, Benkelfat C, Parent S, Dagher A, Vitaro F, Boivin M, Pihl RO, Côté S, Tremblay RE, Séguin JR, Leyton M 32413893
CSBN
11 Extra-striatal D2/3 receptor availability in youth at risk for addiction. Jaworska N, Cox SML, Tippler M, Castellanos-Ryan N, Benkelfat C, Parent S, Dagher A, Vitaro F, Boivin M, Pihl RO, Côté SM, Tremblay RE, Séguin JR, Leyton M 32259831
CSBN
12 Cannabis legalization: Did we make a mistake? Update 2019 Leyton M 31452361
PSYCHOLOGY
13 Legalizing marijuana. Leyton M 26898727
CSBN
14 Cocaine cue-induced dopamine release in the human prefrontal cortex. Milella MS, Fotros A, Gravel P, Casey KF, Larcher K, Verhaeghe JA, Cox SM, Reader AJ, Dagher A, Benkelfat C, Leyton M 26900792
CSBN
15 Dopamine and light: effects on facial emotion recognition. Cawley E, Tippler M, Coupland NJ, Benkelfat C, Boivin DB, Aan Het Rot M, Leyton M 28633582
CSBN
16 Are people with psychiatric disorders violent? Leyton M 29688170
CSBN
17 Are people with psychiatric disorders violent? Leyton M 29947604
CSBN
18 Neuroimaging tests for clinical psychiatry: Are we there yet? Leyton M, Kennedy SH 28639935
IMAGING
19 Dopamine cross-sensitization between psychostimulant drugs and stress in healthy male volunteers. Booij L, Welfeld K, Leyton M, Dagher A, Boileau I, Sibon I, Baker GB, Diksic M, Soucy JP, Pruessner JC, Cawley-Fiset E, Casey KF, Benkelfat C 26905412
PSYCHOLOGY
20 Effect of (Z)-isomer content on [11C]ABP688 binding potential in humans. Smart K, Cox SML, Kostikov A, Shalai A, Scala SG, Tippler M, Jaworska N, Boivin M, Séguin JR, Benkelfat C, Leyton M 30607444
CSBN
21 Sex differences in [11C]ABP688 binding: a positron emission tomography study of mGlu5 receptors. Smart K, Cox SML, Scala SG, Tippler M, Jaworska N, Boivin M, Séguin JR, Benkelfat C, Leyton M 30627817
CSBN
22 Posterior dopamine D2/3 receptors and brain network functional connectivity. Nagano-Saito A, Lissemore JI, Gravel P, Leyton M, Carbonell F, Benkelfat C 28700819
PERFORM

 

Title:Extra-striatal D2/3 receptor availability in youth at risk for addiction.
Authors:Jaworska NCox SMLTippler MCastellanos-Ryan NBenkelfat CParent SDagher AVitaro FBoivin MPihl ROCôté SMTremblay RESéguin JRLeyton M
Link:https://www.ncbi.nlm.nih.gov/pubmed/32259831?dopt=Abstract
DOI:10.1038/s41386-020-0662-7
Publication:Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Keywords:
PMID:32259831 Category:Neuropsychopharmacology Date Added:2020-04-08
Dept Affiliation: CSBN
1 Institute of Mental Health Research, affiliated with the University of Ottawa, Ottawa, ON, Canada.
2 Department of Cellular & Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.
3 Department of Psychiatry, McGill University, Montreal, QC, Canada.
4 Montreal Neurological Institute, McGill University, Montreal, QC, Canada.
5 School of Psychoeducation, Université de Montréal, Montreal, QC, Canada.
6 CHU Ste-Justine Research Center, Montreal, QC, Canada.
7 Department of Psychology, Université Laval, Montreal, QC, Canada.
8 Department of Psychology, McGill University, Montreal, QC, Canada.
9 Department of Social & Preventative Medicine, Université de Montréal, Montreal, QC, Canada.
10 Department of Pediatrics & Psychology, Université de Montréal, Montreal, QC, Canada.
11 Department of Psychiatry, Université de Montréal, Montreal, QC, Canada.
12 Department of Psychiatry, McGill University, Montreal, QC, Canada. marco.leyton@mcgill.ca.
13 Montreal Neurological Institute, McGill University, Montreal, QC, Canada. marco.leyton@mcgill.ca.
14 CHU Ste-Justine Research Center, Montreal, QC, Canada. marco.leyton@mcgill.ca.
15 Department of Psychology, McGill University, Montreal, QC, Canada. marco.leyton@mcgill.ca.
16 Center for Studies in Behavioral Neurobiology, Concordia University, Montreal, QC, Canada. marco.leyton@mcgill.ca.

Description:

Extra-striatal D2/3 receptor availability in youth at risk for addiction.

Neuropsychopharmacology. 2020 Apr 07;:

Authors: Jaworska N, Cox SML, Tippler M, Castellanos-Ryan N, Benkelfat C, Parent S, Dagher A, Vitaro F, Boivin M, Pihl RO, Côté SM, Tremblay RE, Séguin JR, Leyton M

Abstract

The neurobiological traits that confer risk for addictions remain poorly understood. However, dopaminergic function throughout the prefrontal cortex, limbic system, and upper brainstem has been implicated in behavioral features that influence addiction vulnerability, including poor impulse control and altered sensitivity to rewards and punishments (i.e., externalizing features). To test these associations in humans, we measured type-2/3 dopamine receptor (DA2/3R) availability in youth at high vs. low risk for substance use disorders (SUDs). In this study, N?=?58 youth (18.5?±?0.6?years) were recruited from cohorts that have been followed since birth. Participants with either high (high EXT; N?=?27; 16?F/11?M) or low pre-existing externalizing traits (low EXT; N?=?31; 20?F/11?M) underwent a 90-min positron emission tomography [18F]fallypride scan, and completed the Barratt impulsiveness scale (BIS-11), substance use risk profile scale (SURPS), and sensitivity to punishment and sensitivity to reward (SR) questionnaire. We found that high vs. low EXT trait participants reported elevated substance use, BIS-11, SR, and SURPS impulsivity scores, had a greater prevalence of psychiatric disorders, and exhibited higher [18F]fallypride binding potential (BPND) values in prefrontal, limbic and paralimbic regions, even when controlling for substance use. Group differences were not evident in midbrain dopamine cell body regions, but, across all participants, low midbrain BPND values were associated with low SP scores. Together, the results suggest that altered DA2/3R availability in terminal extra-striatal and dopamine cell body regions might constitute biological vulnerability traits, generating an EXT trajectory for addictions with and without co-occurring alterations in punishment sensitivity (i.e., an internalizing feature).

PMID: 32259831 [PubMed - as supplied by publisher]





BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University